{
    "id": 11620,
    "fullName": "BRCA2 del",
    "impact": "deletion",
    "proteinEffect": "loss of function",
    "geneVariantDescriptions": [
        {
            "description": "BRCA2 del indicates a deletion of the BRCA2 gene.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 675,
        "geneSymbol": "BRCA2",
        "terms": [
            "BRCA2",
            "BRCC2",
            "BROVCA2",
            "FACD",
            "FAD",
            "FAD1",
            "FANCD",
            "FANCD1",
            "GLM3",
            "PNCA2",
            "XRCC11"
        ]
    },
    "variant": "del",
    "createDate": "09/08/2015",
    "updateDate": "07/30/2019",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 3063,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Platinol (cisplatin) inhibited growth of a human colorectal adenocarcinoma cell line harboring BRCA2 deletion in culture, and inhibited tumor growth in xenograft models (PMID: 25193512).",
            "molecularProfile": {
                "id": 11671,
                "profileName": "BRCA2 del"
            },
            "therapy": {
                "id": 700,
                "therapyName": "Cisplatin",
                "synonyms": null
            },
            "indication": {
                "id": 50861,
                "name": "colorectal adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3461,
                    "pubMedId": 25193512,
                    "title": "Dual targeting of hypoxia and homologous recombination repair dysfunction in triple-negative breast cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25193512"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19474,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a BRCA2 knockout colon cancer cell line did not confer sensitivity to AZD7648 treatment compared to BRCA2-positive cells in culture (PMID: 31699977).",
            "molecularProfile": {
                "id": 11671,
                "profileName": "BRCA2 del"
            },
            "therapy": {
                "id": 8900,
                "therapyName": "AZD7648",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 16922,
                    "pubMedId": 31699977,
                    "title": "AZD7648 is a potent and selective DNA-PK inhibitor that enhances radiation, chemotherapy and olaparib activity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31699977"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3066,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colorectal adenocarcinoma cells with BRCA2 deletion demonstrated increased sensitivity to Ambochlorin (chlorambucil) compared to cells with intact BRCA2 in culture (PMID: 25193512).",
            "molecularProfile": {
                "id": 11671,
                "profileName": "BRCA2 del"
            },
            "therapy": {
                "id": 3035,
                "therapyName": "Chlorambucil",
                "synonyms": null
            },
            "indication": {
                "id": 50861,
                "name": "colorectal adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3461,
                    "pubMedId": 25193512,
                    "title": "Dual targeting of hypoxia and homologous recombination repair dysfunction in triple-negative breast cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25193512"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3065,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colorectal adenocarcinoma cells with BRCA2 deletion demonstrated increased sensitivity to Evofosfamide (TH-302) compared to cells with intact BRCA2 in culture and human cell line xenograft models (PMID: 25193512).",
            "molecularProfile": {
                "id": 11671,
                "profileName": "BRCA2 del"
            },
            "therapy": {
                "id": 1317,
                "therapyName": "Evofosfamide",
                "synonyms": null
            },
            "indication": {
                "id": 50861,
                "name": "colorectal adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3461,
                    "pubMedId": 25193512,
                    "title": "Dual targeting of hypoxia and homologous recombination repair dysfunction in triple-negative breast cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25193512"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20456,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II (TOPARP-B) trial, Lynparza (olaparib) treatment resulted in a composite overall response rate of 83.3% (25/30) and a RECIST objective response rate of 52.4% (11/21) in patients with castration-resistant prostate cancer harboring deleterious mutations or homozygous deletion of BRCA1/2 (PMID: 31806540; NCT01682772).",
            "molecularProfile": {
                "id": 11671,
                "profileName": "BRCA2 del"
            },
            "therapy": {
                "id": 837,
                "therapyName": "Olaparib",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 17849,
                    "pubMedId": 31806540,
                    "title": "Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31806540"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 3064,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colorectal adenocarcinoma cells with BRCA2 deletion demonstrated increased sensitivity to PR-104 compared to cells with intact BRCA2 in culture and in cell line xenograft models (PMID: 25193512)",
            "molecularProfile": {
                "id": 11671,
                "profileName": "BRCA2 del"
            },
            "therapy": {
                "id": 3029,
                "therapyName": "PR-104",
                "synonyms": null
            },
            "indication": {
                "id": 50861,
                "name": "colorectal adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3461,
                    "pubMedId": 25193512,
                    "title": "Dual targeting of hypoxia and homologous recombination repair dysfunction in triple-negative breast cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25193512"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17321,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Imfinzi (durvalumab) plus Lynparza (olaparib) resulted in PSA decrease of at least 50% in 53% (9/17) of metastatic castrate-resistant prostate cancer patients, with 3 responders harboring germline frameshift BRCA2 mutations and somatic deletion of the other allele, and 2 others with homozygous BRCA2 alterations, and resulted in a 12-mo. PFS probability of 83.3% in patients with mutations in DNA damage repair genes, compared to 36.4% in patients without (PMID: 30514390; NCT02484404).",
            "molecularProfile": {
                "id": 32502,
                "profileName": "BRCA2 del BRCA2 inact mut"
            },
            "therapy": {
                "id": 2894,
                "therapyName": "Durvalumab + Olaparib",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 15371,
                    "pubMedId": 30514390,
                    "title": "Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30514390"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 11671,
            "profileName": "BRCA2 del",
            "profileTreatmentApproaches": [
                {
                    "id": 16734,
                    "name": "PARP Inhibitor (Pan)",
                    "profileName": "BRCA2 del"
                },
                {
                    "id": 16735,
                    "name": "PARP-1 Inhibitor",
                    "profileName": "BRCA2 del"
                }
            ]
        },
        {
            "id": 32502,
            "profileName": "BRCA2 del BRCA2 inact mut",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}